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phe treatment of aortic valve disease is undergoing rapid
hanges. In addition to conventional valve replacement that
as evolved as the gold standard over several decades,
ranscatheter techniques have been introduced into clinical
ractice. Whereas the conventional approach offers very
recise and safe suturing of standard valves with low failure
ates and excellent proven long-term outcomes, transcath-
ter techniques allow for off-pump beating-heart valve
mplantations that can even be performed without general
nesthesia in some patients. To determine the clinical benefits
f transcatheter valve implantation in comparison with con-
entional aortic valve surgery, randomized trials are required.
See page 1883
iven the lack of data from randomized trials, the study by
lavel et al. (1) in this issue of the Journal is timely and
rovides insight into the hemodynamic performance of
nterventional and standard aortic valve implants. Pibarot’s
roup from Quebec and Webb’s group from Vancouver are
ioneers both in the field of hemodynamic assessment of
rosthetic heart valves and in transcatheter aortic valve
mplantations.
Hemodynamic assessment was performed retrospectively
n a total of 150 patients, of whom 50 received transfemoral
r transapical aortic valve implantation, and the remaining
00 patients received conventional aortic valve replacement
sing a stented (n  50) or a stentless (n  50) xenograft.
f note, 39 of 89 patients with transcatheter valve implan-
ation had to be excluded from the analysis owing to
rocedural death (9%), death before completing their 6- or
2-month follow-up (14.6%), or incomplete follow-up
20.2%). Similar data were not provided for the stented or
tentless valve groups. Groups were matched for standard
riteria, including the aortic annulus diameter. Particularly
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witzerland. Dr. Walther infrequently receives a speaker’s honorarium, a lowerl
mount, from Edwards Lifesciences, Inc. (Irvine, California), which manufactures
nd distributes the transcatheter heart valves used in this study.n the stented valve group, a large number (18%) of 19-mm
alves, known for high transvalvular gradients, were im-
lanted. Another 40% of patients in the stented group and
4% in the stentless group received 21-mm valves. The
mallest transcatheter valve implanted was 23 mm. Con-
ersely, 64% of the patients in the transcatheter group
eceived a 26-mm valve, and only 10% in the stented group
nd 26% in the stentless group received a 25-mm valve.
learly, this disproportional selection of implants is related
o the oversizing concept. During transcatheter aortic valve
mplantation, oversizing as much as 2 to 3 mm is usually
erformed to generate the radial forces required to achieve a
table position of the implant. Not surprisingly, the authors
ound transvalvular gradients to be lower in the transcath-
ter group at discharge. Whether a total difference of mean
ransvalvular gradient of 3 (transcatheter vs. stentless) or 4
m Hg (transcatheter vs. stented), albeit statistically sig-
ificant, has any clinical relevance remains unclear at this
oint. At 1 year, transvalvular gradients remained signifi-
antly lower in the transcatheter versus the stented xenograft
roup, whereas they were equal between the transcatheter
nd the stentless group, even though the stentless valves had
smaller diameter at the time of implant.
After transcatheter aortic valve implantation, patients had
significantly higher incidence of aortic regurgitation (present
n 50% of patients) in comparison with conventional surgery
present in 10% [stented valves] and 12% [stentless valves]
f patients, respectively), which persisted largely unchanged
hroughout the study.
The observed immediate improvement in left ventricular
LV) ejection fraction after implantation in the transcathe-
er group may most likely reflect that the procedure is
erformed on the beating nonischemic heart. Despite myo-
ardial protection, surgical implantation on the arrested
eart may cause some impairment of ventricular function.
owever, echocardiography tends to overestimate LV ejec-
ion fraction in the presence of aortic regurgitation, which
as present in 50% of the transcatheter patients after
ntervention.
Valve surgery for aortic valve stenosis aims to provide a
ow transvalvular gradient, induced regression of hypertro-
hy and recovery of LV function, freedom from paravalvulareak, long-term freedom from structural failure, and long-
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May 19, 2009:1892–3 Transcatheter Valve Hemodynamicserm freedom from valve-related reoperation. Most contem-
orary xenografts offer sufficient hemodynamic improve-
ent to achieve regression of LV hypertrophy, and thus
ormalize ventricular function even when some residual
radient persists. In this context, the observed differences in
ean gradients of 3 and 4 mm Hg for the 3 groups
ost-operatively may have limited clinical importance. The
uthors emphasize the high incidence of patient-prosthesis
ismatch in the conventionally treated group. The potential
mpact of patient-prosthesis mismatch on long-term sur-
ival remains a matter of lively debate. While some groups
upport this view, others have not found patient-prosthesis
ismatch to be an independent predictor of survival.
The higher incidence of paravalvular leakage in the
ranscatheter group could, however, become of clinical
mportance, as paravalvular leakage is known to trigger
emolysis, promote endocarditis, and if moderate to severe,
ay even cause LV dysfunction. Longer term follow-up is
equired to determine these outcome parameters.
Common criteria for the hemodynamic evaluation of the
erformance of aortic valve prostheses have been blood flow
elocity, pressure gradients, and effective orifice area. Given
he presented data and the data reported from other groups,
t is fair to state that transcatheter implants match and may
ven exceed the hemodynamic expectations for valvular
mplants, even though the native valve is not replaced but
emains in situ.
But there is a price to pay: namely, a high incidence of
aravalvular leakage, which can be explained by the differ-
nces in the technical approach. Whereas conventional
alves can be safely implanted using precise suturing tech-
iques, transcatheter valves are implanted in a sutureless
ashion using oversizing to expand a stent at the level of the
ortic annulus. The technical constraints posed by the aranscatheter technique have promoted a paradigm shift
ith regard to the hemodynamic assessment of prosthetic
eart valves. Cardiac surgeons were educated over the years
o judge paravalvular leakage as a complication of surgery.
ith the event of transcatheter techniques, paravalvular
eaks are now considered as acceptable collateral damage
ntrinsic to the procedure. It is true that trivial and mild
aravalvular incompetence in patients with a hypertrophied
entricle is usually well tolerated. As long as a negative
mpact of the high incidence of paravalvular leakage on
ong-term results cannot be ruled out, a word of caution is
ustified.
In the future, aortic valve prostheses designed for trans-
atheter implantations will have to match standard criteria
or accepted quality: in addition to long-term durability,
ase of implantation, and safety of positioning, a low incidence
nd degree of potential paravalvular leakage will be impor-
ant end points. It is quite clear that—especially when
argeting a younger population—the high standards of
uality that have evolved with conventional aortic valve
urgery will have to be matched by any new transcatheter
echnique.
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